The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-arm phase 2 study of the FGFR inhibitor futibatinib (Futi) in combination with pembrolizumab (Pem) in patients with FGF19 expressing advanced or metastatic hepatocellular carcinoma (aHCC).
 
Mathias Palmer
No Relationships to Disclose
 
Angela Ulrich
No Relationships to Disclose
 
Wen Wee Ma
Consulting or Advisory Role - Kodikaz Therapeutic Solutions
Research Funding - Elucida Oncology (Inst); Genentech (Inst); GI Innovation (Inst); Jacobio (Inst); Krystal Biotech (Inst); Kumquat Biosciences (Inst); Lilly (Inst); Takeda (Inst)
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Mitesh Borad
Consulting or Advisory Role - Genentech; Guardant Health; Kriya Therapeutics; Senti Biosciences; Tempus; Zymeworks
Research Funding - Adaptimmune (Inst); AstraZeneca (Inst); Basilea (Inst); Biond Biologics (Inst); Compass Therapeutics (Inst); Elevar Therapeutics (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Merck Serono (Inst); Nuvectis Pharma (Inst); Qurient (Inst); RedHill Biopharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Seagen (Inst); ZielBio (Inst)
 
Hani Babiker
Consulting or Advisory Role - Caris MPI; Celgene; Endocyte; Guardant Health; Idera; Incyte; Ipsen; Myovant Sciences; Novocure
Speakers' Bureau - Guardant Health
Research Funding - AstraZeneca (Inst); BMS (Inst); Dragonfly Therapeutics (Inst); Elevation Oncology (Inst); HiFiBiO Therapeutics (Inst); Incyte (Inst); JSI (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Qurient (Inst); Revolution Health Care (Inst); Spirita Oncology (Inst); Strategia (Inst); Zelbio (Inst)
 
Umair Majeed
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
 
Alexander Revzin
Employment - Sersense (I)
Leadership - Sersense (I)
Stock and Other Ownership Interests - Sersense (I)
Research Funding - Sersense
 
Gregory Gores
Honoraria - Sagimet Biosciences
 
Thorvardur Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Biomea Fusion; Boehringer Ingelheim; Camurus (Inst); Crinetics Pharmaceuticals (Inst); Curium Pharma; Exelixis; Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Perspective Therapeutics (Inst); Tersera; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society
 
Zhaohui Jin
Consulting or Advisory Role - Elevar Therapeutics (Inst); Exelixis (Inst); Innovent Biologics (Inst)
 
Lionel Aurelien Kankeu Fonkoua
Honoraria - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)
Consulting or Advisory Role - Exelixis (Inst); Incyte (Inst); S2N Health (Inst)
 
Robert McWilliams
Stock and Other Ownership Interests - Zentalis
Consulting or Advisory Role - Tempus (Inst)
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline/Tesaro (Inst); Merck (Inst); Newlink Genetics (Inst)
 
Lewis Roberts
Honoraria - Keystone Symposia; PEER Education
Consulting or Advisory Role - Alphasights; Chan Zuckerberg Initiative; Exact Sciences (Inst); PROMETRIKA; Total Lifestyle Change, Inc; Vanderbilt University Medical Center
Research Funding - Exact Sciences (Inst); Gilead Sciences (Inst); Glycotest (Inst); Innovo Bioanalysis (Inst); Wako Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - Springer Book Royalties; US Patent No. 9,469,877: Materials and Methods for Diagnosis, Prognosis, Monitoring of Recurrence and Assessment of Therapeutic/Prophylactic Treatment of Pancreaticobiliary Cancer (Inst)
 
Rondell Graham
Research Funding - Astellas Pharma (Inst); Daiichi Sankyo/Astra Zeneca
 
Ajit Goenka
Honoraria - Continental Hospitals
Consulting or Advisory Role - ClearNote Health; Ferronova; GE Healthcare; UWorld
Research Funding - Novartis; SOFIE
Travel, Accommodations, Expenses - Continental Hospitals
 
Julie Heimbach
No Relationships to Disclose
 
Amit Mahipal
Consulting or Advisory Role - AstraZeneca/MedImmune; Elevar Therapeutics; Guardant Health; Taiho Oncology
Speakers' Bureau - AstraZeneca; Exelixis; Taiho Oncology
Research Funding - Taiho Pharmaceutical
 
Fang-Shu Ou
No Relationships to Disclose
 
Nguyen Tran
Consulting or Advisory Role - AstraZeneca (Inst); DAVA Oncology (Inst); Elevar Therapeutics (Inst); Exelixis (Inst); Ipsen (Inst); QED Therapeutics (Inst); TEMPUS (Inst)
Speakers' Bureau - DAVA oncology (Inst)
Research Funding - Exact Sciences